Key result
OSA is strongly linked to metabolic diseases including obesity, insulin resistance, T2DM, and NAFLD.
This review highlights the strong association between obstructive sleep apnea syndrome and metabolic diseases such as obesity, type 2 diabetes, and nonalcoholic fatty liver disease.
May prompt OSA screening in metabolic disease patients; leaves open causality and treatment effects on outcomes.
With the rapid changes in lifestyle in modern society, including the high nutritional intake and reduced physical activity, the incidence of metabolic diseases has been increasing year by year. Obstructive sleep apnea syndrome (OSAS) is a sleep disorder, usually characterized by sudden pauses of breathing during sleep and an interrupted sleep rhythm. Although the pathological mechanism remains poorly understood, it has been strongly associated with metabolic diseases, including obesity, insulin resistance, type 2 diabetes mellitus (T2DM), and nonalcoholic fatty liver disease (NAFLD). In the present mini-review, we briefly summarize the connections between OSAS, obesity, T2DM, and NAFLD, which might help us to better understand the pathogenesis of human diseases.
No takes yet. Share an insight, caveat, or question.
Li et al. (2018) conducted a review in Obstructive sleep apnea syndrome and metabolic diseases. Obstructive sleep apnea syndrome was evaluated. Obstructive sleep apnea syndrome is strongly associated with metabolic diseases, including obesity, insulin resistance, type 2 diabetes mellitus, and nonalcoholic fatty liver disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: